Candidate: CiVax™ (heat stable COVID-19 vaccine program) ●

Category: VAX

Type: Vaccine based on heat stable subunit filovirus platform, with enhanced stability at elevated temperatures.

2021 Status: Preclinical progress reported—Soligenix said March 4 that researchers had posted preclinical immunogenicity studies for CiVax™ confirming rapid-onset, broad-spectrum, neutralizing antibody and cell-mediated immunity using full-length Spike protein antigens. A preprint study titled “Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice,” was posted in bioRxiv. Research will continue, Soligenix said, under a $1.5M Small Business Innovation Research (SBIR) grant awarded to Soligenix in December 2020.

2020 Status: Soligenix said March 23 its ongoing collaboration with UH Mānoa was expanding to include vaccines against COVID-19. The partners will use a vaccine platform that includes a viral surface glycoprotein designed to mediate entry and fusion of the virus with host cells and is manufactured with a proprietary insect cell expression system coupled with protein-specific affinity purification. The protein antigen is one of three essential components of the platform; the other two are an adjuvant shown to enhance both cell mediated and humoral immunity, and a formulation which enables thermostabilization of the resulting mixture, avoiding the need for cold chain storage and shipping.

Soligenix’s Public Health Solutions business segment is partnering with Axel Lehrer, PhD, of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (JABSOM).

COVID-19: 300 Candidates and Counting

To navigate through the >300 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:


Previous articleOrganicell Regenerative Medicine – Zofin™ (Organcell™ Flow)
Next articleAJ Vaccines